Eprosartan: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
CheMoBot (talk | contribs)
Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'ChEBI_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_Pharmacology|err
BogBot (talk | contribs)
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
Line 1: Line 1:
{{Drugbox| verifiedrevid = 443731045
{{Drugbox
| verifiedrevid = 443731045
| IUPAC_name = 4-({2-butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1''H''-imidazol-1-yl}methyl)benzoic acid
|
| image = Eprosartan.svg
|IUPAC_name = 4-({2-butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1''H''-imidazol-1-yl}methyl)benzoic acid

| image=Eprosartan.svg
<!--Clinical data-->
| tradename = Teveten
| Drugs.com = {{drugs.com|monograph|teveten}}
| MedlinePlus = a601237
| pregnancy_category = ?
| legal_status = ?
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 15% (Eprosartan mesylate)
| metabolism = not metabolized
| elimination_half-life = 5 to 9 hours
| excretion = [[Renal]] 10%, [[biliary]] 90%

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number = 133040-01-4
| ATC_prefix = C09
| ATC_suffix = CA02
| PubChem = 5281037
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = APRD00950
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4444504
| ChemSpiderID = 4444504
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 813
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2KH13Z0S0Y
| UNII = 2KH13Z0S0Y
| KEGG_Ref = {{keggcite|correct|kegg}}
| InChI = 1/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
| KEGG = D04040
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4814
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 813

<!--Chemical data-->
| C=23 | H=24 | N=2 | O=4 | S=1
| molecular_weight = Eprosartan mesylate: 520.625 g/mol
| smiles = O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
| smiles = O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
| InChI = 1/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
| InChIKey = OROAFUQRIXKEMV-LDADJPATBR
| InChIKey = OROAFUQRIXKEMV-LDADJPATBR
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
Line 17: Line 47:
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OROAFUQRIXKEMV-LDADJPATSA-N
| StdInChIKey = OROAFUQRIXKEMV-LDADJPATSA-N
| CAS_number=133040-01-4
| ATC_prefix=C09
| ATC_suffix=CA02
| ATC_supplemental=
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4814
| PubChem=5281037
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank=APRD00950
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04040
| C=23 | H=24 | N=2 | O=4 | S=1
| molecular_weight = Eprosartan mesylate: 520.625 g/mol
| bioavailability= 15% (Eprosartan mesylate)
| metabolism = not metabolized
| elimination_half-life= 5 to 9 hours
| excretion = [[Renal]] 10%, [[biliary]] 90%
| pregnancy_category = ?
| legal_status = ?
| routes_of_administration= Oral
}}
}}



Revision as of 09:48, 28 August 2011

Eprosartan
Clinical data
Trade namesTeveten
AHFS/Drugs.comMonograph
MedlinePlusa601237
Pregnancy
category
  • ?
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Bioavailability15% (Eprosartan mesylate)
Metabolismnot metabolized
Elimination half-life5 to 9 hours
ExcretionRenal 10%, biliary 90%
Identifiers
  • 4-({2-butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H24N2O4S
Molar massEprosartan mesylate: 520.625 g/mol g·mol−1
3D model (JSmol)
  • O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
  • InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ checkY
  • Key:OROAFUQRIXKEMV-LDADJPATSA-N checkY
  (verify)

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed as Teveten by Abbott Laboratories in the United States.It is marketed as Eprozar by INTAS Pharmaceuticals in the INDIA and by Solvay Pharmaceuticals elsewhere. It is sometimes paired with hydrochlorothiazide, marketed in the US as Teveten HCT and elsewhere as Teveten Plus.

The drug acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[1]

See also

Angiotensin Receptor Blockers: Drug discovery and development

External links

References

  1. ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061.{{cite journal}}: CS1 maint: multiple names: authors list (link)